

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Male

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline		Xanomeline High Dose (N=72)
		n	(%)	
ANY EVENT: ANY EVENT	69 (80%)	86	(90%)	70 (97%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS: ANY EVENT	0 (0%)	1	(1%)	2 (3%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	1	(1%)	2 (3%)
EAR AND LABYRINTH DISORDERS: ANY EVENT	1 (1%)	2	(2%)	1 (1%)
CERUMEN IMPACTION	0 (0%)	1	(1%)	0 (0%)
EAR PAIN	1 (1%)	0	(0%)	0 (0%)
TINNITUS	0 (0%)	1	(1%)	0 (0%)
VERTIGO	0 (0%)	1	(1%)	1 (1%)
EYE DISORDERS: ANY EVENT	4 (5%)	2	(2%)	1 (1%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1	(1%)	0 (0%)
CONJUNCTIVITIS	2 (2%)	0	(0%)	0 (0%)
EYE ALLERGY	1 (1%)	0	(0%)	0 (0%)
EYE PRURITUS	1 (1%)	0	(0%)	0 (0%)
EYE SWELLING	1 (1%)	0	(0%)	0 (0%)
GLAUCOMA	1 (1%)	0	(0%)	0 (0%)
VISION BLURRED	0 (0%)	1	(1%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Male

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline		Xanomeline High Dose (N=72)	
		Low Dose (N=96)			
		n	(%)		
HEPATOBILIARY DISORDERS: ANY EVENT	1 (1%)	0	(0%)	0 (0%)	
HYPERBILIRUBINAEMIA	1 (1%)	0	(0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS: ANY EVENT	0 (0%)	1	(1%)	1 (1%)	
HYPERSENSITIVITY	0 (0%)	1	(1%)	0 (0%)	
SEASONAL ALLERGY	0 (0%)	0	(0%)	1 (1%)	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS: ANY EVENT	4 (5%)	5	(5%)	5 (7%)	
CONTUSION	1 (1%)	1	(1%)	2 (3%)	
EXCORIATION	2 (2%)	1	(1%)	1 (1%)	
FACIAL BONES FRACTURE	0 (0%)	0	(0%)	1 (1%)	
FALL	1 (1%)	2	(2%)	1 (1%)	
HIP FRACTURE	1 (1%)	0	(0%)	2 (3%)	
JOINT DISLOCATION	0 (0%)	1	(1%)	0 (0%)	
SKIN LACERATION	1 (1%)	2	(2%)	0 (0%)	
WOUND	0 (0%)	1	(1%)	0 (0%)	

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Male

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline	
		Low Dose (N=96)	High Dose (N=72)
METABOLISM AND NUTRITION DISORDERS: ANY EVENT	6 (7%)	1 (1%)	3 (4%)
DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)
FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)
HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)
INCREASED APPETITE	1 (1%)	0 (0%)	1 (1%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS: ANY EVENT	5 (6%)	7 (7%)	8 (11%)
ARTHRALGIA	1 (1%)	2 (2%)	1 (1%)
ARTHRITIS	1 (1%)	0 (0%)	1 (1%)
BACK PAIN	1 (1%)	1 (1%)	3 (4%)
FLANK PAIN	0 (0%)	0 (0%)	2 (3%)
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)
MUSCULAR WEAKNESS	0 (0%)	1 (1%)	0 (0%)
MYALGIA	0 (0%)	0 (0%)	1 (1%)
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)
SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Male

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline		Xanomeline High Dose (N=72)
		n	(%)	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS): ANY EVENT	0 (0%)	2	(2%)	1 (1%)
COLON CANCER	0 (0%)	1	(1%)	0 (0%)
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1	(1%)	0 (0%)
PROSTATE CANCER	0 (0%)	0	(0%)	1 (1%)
RENAL AND URINARY DISORDERS: ANY EVENT	4 (5%)	4	(4%)	3 (4%)
CALCULUS URETHRAL	0 (0%)	0	(0%)	1 (1%)
DYSURIA	1 (1%)	1	(1%)	0 (0%)
ENURESIS	0 (0%)	1	(1%)	0 (0%)
INCONTINENCE	0 (0%)	1	(1%)	0 (0%)
MICTURITION URGENCY	1 (1%)	1	(1%)	1 (1%)
NEPHROLITHIASIS	1 (1%)	0	(0%)	1 (1%)
POLLAKIURIA	1 (1%)	0	(0%)	0 (0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS: ANY EVENT	2 (2%)	0	(0%)	1 (1%)
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0	(0%)	1 (1%)
PELVIC PAIN	1 (1%)	0	(0%)	0 (0%)
SOCIAL CIRCUMSTANCES: ANY EVENT	0 (0%)	0	(0%)	1 (1%)
ALCOHOL USE	0 (0%)	0	(0%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
Gender: Male

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline	
		Low Dose (N=96)	High Dose (N=72)
SURGICAL AND MEDICAL PROCEDURES: ANY EVENT	2 (2%)	1 (1%)	2 (3%)
ACROCHORDON EXCISION	0 (0%)	0 (0%)	1 (1%)
CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)
SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)
VASCULAR DISORDERS: ANY EVENT	3 (3%)	4 (4%)	1 (1%)
HOT FLUSH	0 (0%)	1 (1%)	0 (0%)
HYPERTENSION	1 (1%)	2 (2%)	0 (0%)
HYPOTENSION	2 (2%)	1 (1%)	0 (0%)
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)
WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Male

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline		Xanomeline High Dose (N=72)
		n	(%)	
ANY EVENT: ANY EVENT	69 (80%)	86	(90%)	70 (97%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS: ANY EVENT	0 (0%)	1	(1%)	2 (3%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	1	(1%)	2 (3%)
EAR AND LABYRINTH DISORDERS: ANY EVENT	1 (1%)	2	(2%)	1 (1%)
CERUMEN IMPACTION	0 (0%)	1	(1%)	0 (0%)
EAR PAIN	1 (1%)	0	(0%)	0 (0%)
TINNITUS	0 (0%)	1	(1%)	0 (0%)
VERTIGO	0 (0%)	1	(1%)	1 (1%)
EYE DISORDERS: ANY EVENT	4 (5%)	2	(2%)	1 (1%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1	(1%)	0 (0%)
CONJUNCTIVITIS	2 (2%)	0	(0%)	0 (0%)
EYE ALLERGY	1 (1%)	0	(0%)	0 (0%)
EYE PRURITUS	1 (1%)	0	(0%)	0 (0%)
EYE SWELLING	1 (1%)	0	(0%)	0 (0%)
GLAUCOMA	1 (1%)	0	(0%)	0 (0%)
VISION BLURRED	0 (0%)	1	(1%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Male

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline		Xanomeline High Dose (N=72)	
		Low Dose (N=96)			
		n	(%)		
HEPATOBILIARY DISORDERS: ANY EVENT	1 (1%)	0	(0%)	0 (0%)	
HYPERBILIRUBINAEMIA	1 (1%)	0	(0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS: ANY EVENT	0 (0%)	1	(1%)	1 (1%)	
HYPERSENSITIVITY	0 (0%)	1	(1%)	0 (0%)	
SEASONAL ALLERGY	0 (0%)	0	(0%)	1 (1%)	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS: ANY EVENT	4 (5%)	5	(5%)	5 (7%)	
CONTUSION	1 (1%)	1	(1%)	2 (3%)	
EXCORIATION	2 (2%)	1	(1%)	1 (1%)	
FACIAL BONES FRACTURE	0 (0%)	0	(0%)	1 (1%)	
FALL	1 (1%)	2	(2%)	1 (1%)	
HIP FRACTURE	1 (1%)	0	(0%)	2 (3%)	
JOINT DISLOCATION	0 (0%)	1	(1%)	0 (0%)	
SKIN LACERATION	1 (1%)	2	(2%)	0 (0%)	
WOUND	0 (0%)	1	(1%)	0 (0%)	

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Male

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline	
		Low Dose (N=96)	High Dose (N=72)
METABOLISM AND NUTRITION DISORDERS: ANY EVENT	6 (7%)	1 (1%)	3 (4%)
DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)
FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)
HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)
INCREASED APPETITE	1 (1%)	0 (0%)	1 (1%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS: ANY EVENT	5 (6%)	7 (7%)	8 (11%)
ARTHRALGIA	1 (1%)	2 (2%)	1 (1%)
ARTHRITIS	1 (1%)	0 (0%)	1 (1%)
BACK PAIN	1 (1%)	1 (1%)	3 (4%)
FLANK PAIN	0 (0%)	0 (0%)	2 (3%)
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)
MUSCULAR WEAKNESS	0 (0%)	1 (1%)	0 (0%)
MYALGIA	0 (0%)	0 (0%)	1 (1%)
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)
SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Male

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline		Xanomeline High Dose (N=72)
		n	(%)	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS): ANY EVENT	0 (0%)	2	(2%)	1 (1%)
COLON CANCER	0 (0%)	1	(1%)	0 (0%)
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1	(1%)	0 (0%)
PROSTATE CANCER	0 (0%)	0	(0%)	1 (1%)
RENAL AND URINARY DISORDERS: ANY EVENT	4 (5%)	4	(4%)	3 (4%)
CALCULUS URETHRAL	0 (0%)	0	(0%)	1 (1%)
DYSURIA	1 (1%)	1	(1%)	0 (0%)
ENURESIS	0 (0%)	1	(1%)	0 (0%)
INCONTINENCE	0 (0%)	1	(1%)	0 (0%)
MICTURITION URGENCY	1 (1%)	1	(1%)	1 (1%)
NEPHROLITHIASIS	1 (1%)	0	(0%)	1 (1%)
POLLAKIURIA	1 (1%)	0	(0%)	0 (0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS: ANY EVENT	2 (2%)	0	(0%)	1 (1%)
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0	(0%)	1 (1%)
PELVIC PAIN	1 (1%)	0	(0%)	0 (0%)
SOCIAL CIRCUMSTANCES: ANY EVENT	0 (0%)	0	(0%)	1 (1%)
ALCOHOL USE	0 (0%)	0	(0%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
Gender: Male

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Xanomeline	
		Low Dose (N=96)	High Dose (N=72)
SURGICAL AND MEDICAL PROCEDURES: ANY EVENT	2 (2%)	1 (1%)	2 (3%)
ACROCHORDON EXCISION	0 (0%)	0 (0%)	1 (1%)
CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)
SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)
VASCULAR DISORDERS: ANY EVENT	3 (3%)	4 (4%)	1 (1%)
HOT FLUSH	0 (0%)	1 (1%)	0 (0%)
HYPERTENSION	1 (1%)	2 (2%)	0 (0%)
HYPOTENSION	2 (2%)	1 (1%)	0 (0%)
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)
WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Female

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline		Yanomeline High Dose (N=72)
		n	(%)	
ANY EVENT: ANY EVENT	69 (80%)	86	(90%)	70 (97%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS: ANY EVENT	0 (0%)	1	(1%)	2 (3%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	1	(1%)	2 (3%)
EAR AND LABYRINTH DISORDERS: ANY EVENT	1 (1%)	2	(2%)	1 (1%)
CERUMEN IMPACTION	0 (0%)	1	(1%)	0 (0%)
EAR PAIN	1 (1%)	0	(0%)	0 (0%)
TINNITUS	0 (0%)	1	(1%)	0 (0%)
VERTIGO	0 (0%)	1	(1%)	1 (1%)
EYE DISORDERS: ANY EVENT	4 (5%)	2	(2%)	1 (1%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1	(1%)	0 (0%)
CONJUNCTIVITIS	2 (2%)	0	(0%)	0 (0%)
EYE ALLERGY	1 (1%)	0	(0%)	0 (0%)
EYE PRURITUS	1 (1%)	0	(0%)	0 (0%)
EYE SWELLING	1 (1%)	0	(0%)	0 (0%)
GLAUCOMA	1 (1%)	0	(0%)	0 (0%)
VISION BLURRED	0 (0%)	1	(1%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Female

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline		Yanomeline High Dose (N=72)	
		Low Dose (N=96)			
		n	(%)		
HEPATOBILIARY DISORDERS: ANY EVENT	1 (1%)	0	(0%)	0 (0%)	
HYPERBILIRUBINAEMIA	1 (1%)	0	(0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS: ANY EVENT	0 (0%)	1	(1%)	1 (1%)	
HYPERSENSITIVITY	0 (0%)	1	(1%)	0 (0%)	
SEASONAL ALLERGY	0 (0%)	0	(0%)	1 (1%)	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS: ANY EVENT	4 (5%)	5	(5%)	5 (7%)	
CONTUSION	1 (1%)	1	(1%)	2 (3%)	
EXCORIATION	2 (2%)	1	(1%)	1 (1%)	
FACIAL BONES FRACTURE	0 (0%)	0	(0%)	1 (1%)	
FALL	1 (1%)	2	(2%)	1 (1%)	
HIP FRACTURE	1 (1%)	0	(0%)	2 (3%)	
JOINT DISLOCATION	0 (0%)	1	(1%)	0 (0%)	
SKIN LACERATION	1 (1%)	2	(2%)	0 (0%)	
WOUND	0 (0%)	1	(1%)	0 (0%)	

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Female

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline	
		Low Dose (N=96)	High Dose (N=72)
METABOLISM AND NUTRITION DISORDERS: ANY EVENT	6 (7%)	1 (1%)	3 (4%)
DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)
FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)
HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)
INCREASED APPETITE	1 (1%)	0 (0%)	1 (1%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS: ANY EVENT	5 (6%)	7 (7%)	8 (11%)
ARTHRALGIA	1 (1%)	2 (2%)	1 (1%)
ARTHRITIS	1 (1%)	0 (0%)	1 (1%)
BACK PAIN	1 (1%)	1 (1%)	3 (4%)
FLANK PAIN	0 (0%)	0 (0%)	2 (3%)
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)
MUSCULAR WEAKNESS	0 (0%)	1 (1%)	0 (0%)
MYALGIA	0 (0%)	0 (0%)	1 (1%)
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)
SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Female

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline		Yanomeline High Dose (N=72)
		n	(%)	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) : ANY EVENT	0 (0%)	2	(2%)	1 (1%)
COLON CANCER	0 (0%)	1	(1%)	0 (0%)
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1	(1%)	0 (0%)
PROSTATE CANCER	0 (0%)	0	(0%)	1 (1%)
RENAL AND URINARY DISORDERS: ANY EVENT	4 (5%)	4	(4%)	3 (4%)
CALCULUS URETHRAL	0 (0%)	0	(0%)	1 (1%)
DYSURIA	1 (1%)	1	(1%)	0 (0%)
ENURESIS	0 (0%)	1	(1%)	0 (0%)
INCONTINENCE	0 (0%)	1	(1%)	0 (0%)
MICTURITION URGENCY	1 (1%)	1	(1%)	1 (1%)
NEPHROLITHIASIS	1 (1%)	0	(0%)	1 (1%)
POLLAKIURIA	1 (1%)	0	(0%)	0 (0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS: ANY EVENT	2 (2%)	0	(0%)	1 (1%)
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0	(0%)	1 (1%)
PELVIC PAIN	1 (1%)	0	(0%)	0 (0%)
SOCIAL CIRCUMSTANCES: ANY EVENT	0 (0%)	0	(0%)	1 (1%)
ALCOHOL USE	0 (0%)	0	(0%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
Gender: Female

This is page value: 1

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline	
		Low Dose (N=96)	High Dose (N=72)
SURGICAL AND MEDICAL PROCEDURES: ANY EVENT	2 (2%)	1 (1%)	2 (3%)
ACROCHORDON EXCISION	0 (0%)	0 (0%)	1 (1%)
CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)
SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)
VASCULAR DISORDERS: ANY EVENT	3 (3%)	4 (4%)	1 (1%)
HOT FLUSH	0 (0%)	1 (1%)	0 (0%)
HYPERTENSION	1 (1%)	2 (2%)	0 (0%)
HYPOTENSION	2 (2%)	1 (1%)	0 (0%)
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)
WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Female

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline		Yanomeline High Dose (N=72)
		n	(%)	
ANY EVENT: ANY EVENT	69 (80%)	86	(90%)	70 (97%)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS: ANY EVENT	0 (0%)	1	(1%)	2 (3%)
VENTRICULAR SEPTAL DEFECT	0 (0%)	1	(1%)	2 (3%)
EAR AND LABYRINTH DISORDERS: ANY EVENT	1 (1%)	2	(2%)	1 (1%)
CERUMEN IMPACTION	0 (0%)	1	(1%)	0 (0%)
EAR PAIN	1 (1%)	0	(0%)	0 (0%)
TINNITUS	0 (0%)	1	(1%)	0 (0%)
VERTIGO	0 (0%)	1	(1%)	1 (1%)
EYE DISORDERS: ANY EVENT	4 (5%)	2	(2%)	1 (1%)
CONJUNCTIVAL HAEMORRHAGE	0 (0%)	1	(1%)	0 (0%)
CONJUNCTIVITIS	2 (2%)	0	(0%)	0 (0%)
EYE ALLERGY	1 (1%)	0	(0%)	0 (0%)
EYE PRURITUS	1 (1%)	0	(0%)	0 (0%)
EYE SWELLING	1 (1%)	0	(0%)	0 (0%)
GLAUCOMA	1 (1%)	0	(0%)	0 (0%)
VISION BLURRED	0 (0%)	1	(1%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Female

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline		Yanomeline High Dose (N=72)	
		Low Dose (N=96)			
		n	(%)		
HEPATOBILIARY DISORDERS: ANY EVENT	1 (1%)	0	(0%)	0 (0%)	
HYPERBILIRUBINAEMIA	1 (1%)	0	(0%)	0 (0%)	
IMMUNE SYSTEM DISORDERS: ANY EVENT	0 (0%)	1	(1%)	1 (1%)	
HYPERSENSITIVITY	0 (0%)	1	(1%)	0 (0%)	
SEASONAL ALLERGY	0 (0%)	0	(0%)	1 (1%)	
INJURY, POISONING AND PROCEDURAL COMPLICATIONS: ANY EVENT	4 (5%)	5	(5%)	5 (7%)	
CONTUSION	1 (1%)	1	(1%)	2 (3%)	
EXCORIATION	2 (2%)	1	(1%)	1 (1%)	
FACIAL BONES FRACTURE	0 (0%)	0	(0%)	1 (1%)	
FALL	1 (1%)	2	(2%)	1 (1%)	
HIP FRACTURE	1 (1%)	0	(0%)	2 (3%)	
JOINT DISLOCATION	0 (0%)	1	(1%)	0 (0%)	
SKIN LACERATION	1 (1%)	2	(2%)	0 (0%)	
WOUND	0 (0%)	1	(1%)	0 (0%)	

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Female

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline	
		Low Dose (N=96)	High Dose (N=72)
METABOLISM AND NUTRITION DISORDERS: ANY EVENT	6 (7%)	1 (1%)	3 (4%)
DECREASED APPETITE	1 (1%)	0 (0%)	1 (1%)
DEHYDRATION	1 (1%)	0 (0%)	0 (0%)
DIABETES MELLITUS	1 (1%)	0 (0%)	0 (0%)
FOOD CRAVING	1 (1%)	1 (1%)	0 (0%)
HYPERCHOLESTEROLAEMIA	0 (0%)	0 (0%)	1 (1%)
HYPONATRAEMIA	1 (1%)	0 (0%)	0 (0%)
INCREASED APPETITE	1 (1%)	0 (0%)	1 (1%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS: ANY EVENT	5 (6%)	7 (7%)	8 (11%)
ARTHRALGIA	1 (1%)	2 (2%)	1 (1%)
ARTHRITIS	1 (1%)	0 (0%)	1 (1%)
BACK PAIN	1 (1%)	1 (1%)	3 (4%)
FLANK PAIN	0 (0%)	0 (0%)	2 (3%)
MUSCLE SPASMS	0 (0%)	1 (1%)	1 (1%)
MUSCULAR WEAKNESS	0 (0%)	1 (1%)	0 (0%)
MYALGIA	0 (0%)	0 (0%)	1 (1%)
PAIN IN EXTREMITY	1 (1%)	0 (0%)	0 (0%)
SHOULDER PAIN	1 (1%)	2 (2%)	0 (0%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
 Gender: Female

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline		Yanomeline High Dose (N=72)
		n	(%)	
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS): ANY EVENT	0 (0%)	2	(2%)	1 (1%)
COLON CANCER	0 (0%)	1	(1%)	0 (0%)
MALIGNANT FIBROUS HISTIOCYTOMA	0 (0%)	1	(1%)	0 (0%)
PROSTATE CANCER	0 (0%)	0	(0%)	1 (1%)
RENAL AND URINARY DISORDERS: ANY EVENT	4 (5%)	4	(4%)	3 (4%)
CALCULUS URETHRAL	0 (0%)	0	(0%)	1 (1%)
DYSURIA	1 (1%)	1	(1%)	0 (0%)
ENURESIS	0 (0%)	1	(1%)	0 (0%)
INCONTINENCE	0 (0%)	1	(1%)	0 (0%)
MICTURITION URGENCY	1 (1%)	1	(1%)	1 (1%)
NEPHROLITHIASIS	1 (1%)	0	(0%)	1 (1%)
POLLAKIURIA	1 (1%)	0	(0%)	0 (0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS: ANY EVENT	2 (2%)	0	(0%)	1 (1%)
BENIGN PROSTATIC HYPERPLASIA	1 (1%)	0	(0%)	1 (1%)
PELVIC PAIN	1 (1%)	0	(0%)	0 (0%)
SOCIAL CIRCUMSTANCES: ANY EVENT	0 (0%)	0	(0%)	1 (1%)
ALCOHOL USE	0 (0%)	0	(0%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.

Table 5: Summary of Treatment Emergent Adverse Events
Gender: Female

This is page value: 2

Body System: Dictionary-Derived Term	Placebo (N=86)	Yanomeline	
		Low Dose (N=96)	High Dose (N=72)
SURGICAL AND MEDICAL PROCEDURES: ANY EVENT	2 (2%)	1 (1%)	2 (3%)
ACROCHORDON EXCISION	0 (0%)	0 (0%)	1 (1%)
CATARACT OPERATION	1 (1%)	1 (1%)	0 (0%)
EYE LASER SURGERY	1 (1%)	0 (0%)	0 (0%)
SKIN LESION EXCISION	0 (0%)	0 (0%)	1 (1%)
VASCULAR DISORDERS: ANY EVENT	3 (3%)	4 (4%)	1 (1%)
HOT FLUSH	0 (0%)	1 (1%)	0 (0%)
HYPERTENSION	1 (1%)	2 (2%)	0 (0%)
HYPOTENSION	2 (2%)	1 (1%)	0 (0%)
ORTHOSTATIC HYPOTENSION	1 (1%)	0 (0%)	0 (0%)
WOUND HAEMORRHAGE	0 (0%)	0 (0%)	1 (1%)

-
- 1.) Only treatment emergent events related to lipids are displayed.
 - 2.) Subjects are only counted once within each body system and preferred term.